Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery
The blood-brain barrier (BBB) is a major hurdle for the development of systemically delivered drugs against diseases of the central nervous system (CNS). Because of this barrier there is still a huge unmet need for the treatment of these diseases, despite years of research efforts across the pharmac...
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-03-01
|
| Series: | Pharmaceutics |
| Subjects: | |
| Online Access: | https://www.mdpi.com/1999-4923/15/4/1100 |
| _version_ | 1797603870720917504 |
|---|---|
| author | Axel H. Meyer Thomas M. Feldsien Mario Mezler Christopher Untucht Ramakrishna Venugopalan Didier R. Lefebvre |
| author_facet | Axel H. Meyer Thomas M. Feldsien Mario Mezler Christopher Untucht Ramakrishna Venugopalan Didier R. Lefebvre |
| author_sort | Axel H. Meyer |
| collection | DOAJ |
| description | The blood-brain barrier (BBB) is a major hurdle for the development of systemically delivered drugs against diseases of the central nervous system (CNS). Because of this barrier there is still a huge unmet need for the treatment of these diseases, despite years of research efforts across the pharmaceutical industry. Novel therapeutic entities, such as gene therapy and degradomers, have become increasingly popular in recent years, but have not been the focus for CNS indications so far. To unfold their full potential for the treatment of CNS diseases, these therapeutic entities will most likely have to rely on innovative delivery technologies. Here we will describe and assess approaches, both invasive and non-invasive, that can enable, or at least increase, the probability of a successful drug development of such novel therapeutics for CNS indications. |
| first_indexed | 2024-03-11T04:38:08Z |
| format | Article |
| id | doaj.art-45d3488e046e4470a84c1662b355c574 |
| institution | Directory Open Access Journal |
| issn | 1999-4923 |
| language | English |
| last_indexed | 2024-03-11T04:38:08Z |
| publishDate | 2023-03-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Pharmaceutics |
| spelling | doaj.art-45d3488e046e4470a84c1662b355c5742023-11-17T20:52:44ZengMDPI AGPharmaceutics1999-49232023-03-01154110010.3390/pharmaceutics15041100Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug DeliveryAxel H. Meyer0Thomas M. Feldsien1Mario Mezler2Christopher Untucht3Ramakrishna Venugopalan4Didier R. Lefebvre5Quantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Knollstraße, 67061 Ludwigshafen, GermanyDrug Delivery and Combination Products, Development Sciences, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USAQuantitative, Translational & ADME Sciences, AbbVie Deutschland GmbH & Co. KG, Knollstraße, 67061 Ludwigshafen, GermanyNeuroscience Discovery, AbbVie Deutschland GmbH & Co. KG, Knollstraße, 67061 Ludwigshafen, GermanyDrug Delivery and Combination Products, Development Sciences, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USADrug Delivery and Combination Products, Development Sciences, AbbVie Inc., 1 N Waukegan Road, North Chicago, IL 60064, USAThe blood-brain barrier (BBB) is a major hurdle for the development of systemically delivered drugs against diseases of the central nervous system (CNS). Because of this barrier there is still a huge unmet need for the treatment of these diseases, despite years of research efforts across the pharmaceutical industry. Novel therapeutic entities, such as gene therapy and degradomers, have become increasingly popular in recent years, but have not been the focus for CNS indications so far. To unfold their full potential for the treatment of CNS diseases, these therapeutic entities will most likely have to rely on innovative delivery technologies. Here we will describe and assess approaches, both invasive and non-invasive, that can enable, or at least increase, the probability of a successful drug development of such novel therapeutics for CNS indications.https://www.mdpi.com/1999-4923/15/4/1100central nervous systemblood brain barrierdrug deliverydegradomernanoparticlesexosomes |
| spellingShingle | Axel H. Meyer Thomas M. Feldsien Mario Mezler Christopher Untucht Ramakrishna Venugopalan Didier R. Lefebvre Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery Pharmaceutics central nervous system blood brain barrier drug delivery degradomer nanoparticles exosomes |
| title | Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery |
| title_full | Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery |
| title_fullStr | Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery |
| title_full_unstemmed | Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery |
| title_short | Novel Developments to Enable Treatment of CNS Diseases with Targeted Drug Delivery |
| title_sort | novel developments to enable treatment of cns diseases with targeted drug delivery |
| topic | central nervous system blood brain barrier drug delivery degradomer nanoparticles exosomes |
| url | https://www.mdpi.com/1999-4923/15/4/1100 |
| work_keys_str_mv | AT axelhmeyer noveldevelopmentstoenabletreatmentofcnsdiseaseswithtargeteddrugdelivery AT thomasmfeldsien noveldevelopmentstoenabletreatmentofcnsdiseaseswithtargeteddrugdelivery AT mariomezler noveldevelopmentstoenabletreatmentofcnsdiseaseswithtargeteddrugdelivery AT christopheruntucht noveldevelopmentstoenabletreatmentofcnsdiseaseswithtargeteddrugdelivery AT ramakrishnavenugopalan noveldevelopmentstoenabletreatmentofcnsdiseaseswithtargeteddrugdelivery AT didierrlefebvre noveldevelopmentstoenabletreatmentofcnsdiseaseswithtargeteddrugdelivery |